# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sir John Franklin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX005-SYN-TD
- Date: 1845-05-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashby-Nwankwo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Pre-departure review two weeks before sailing. **S**

## History of present illness

Sir John sails in two weeks. His home readings this week average 126/78 on amlodipine 5 mg, with no side effects. He has lost 3.9 kg since intake by his own plan and counts his weight goal as met. He is sleeping well and is busy and cheerful; he knows the polar winters will be long and dark and has planned a routine of work, lessons and exercise for the officers and men. He has his clothing, a home blood pressure monitor with a spare cuff, and copies of his medical plan for the ship's surgeons. He has had every planned vaccine except the second zoster dose, due today. **S**

| Element | Detail |
|---|---|
| Home readings | Seven-day average 126/78 mmHg |
| Weight | 86.9 kg, from 90.8 at intake |
| Mood | PHQ-9 2, item 9 scored 0; GAD-7 3 |
| Vitamin D | 34 ng/mL on vitamin D3 |
| Kidney function | Creatinine 0.96 mg/dL, eGFR 90; potassium 4.3 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; sleeping seven hours |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Ears, nose, mouth, and throat | Positive | Trouble hearing in noisy rooms, unchanged |
| Psychiatric | Negative | Mood good; no worry he cannot manage |

4 systems reviewed. **S**

## Current medications

- Amlodipine 5 mg oral tablet once daily **S**
- Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily, continued through the polar winters **S**
- Vitamin C (ascorbic acid) 250 mg oral tablet once daily for the whole expedition, stored sealed and away from heat and light, in addition to food sources **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/76 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 86.9 kg; BMI 30.1 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 0.96 mg/dL; eGFR: 90 mL/min/1.73 m²; 25-hydroxyvitamin D: 34 ng/mL; PHQ-9: 2; GAD-7: 3. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Creatinine: 0.98 mg/dL at baseline, 0.96 mg/dL at this visit **S**
- eGFR: 88 mL/min/1.73 m² at baseline, 90 mL/min/1.73 m² at this visit **S**
- 25-hydroxyvitamin D: 22 ng/mL (low) at baseline, 34 ng/mL at this visit **S**
- PHQ-9: 3 at baseline, 2 at this visit **S**
- GAD-7: 2 at baseline, 3 at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, second of two doses **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/76, pulse 68; weight 86.9 kg, BMI 30.1; waist 101 cm |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Skin | Hands, feet and face intact; no old cold injury |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Essential hypertension on amlodipine** (I10). Controlled at 126/78 at home on amlodipine 5 mg; kidney function and potassium normal as a baseline for the years away. **S**
   - Amlodipine 5 mg daily: a three-year supply in blister packs, split between the two ships.
   - Weekly home readings on board; written instructions for the ship's surgeons to raise the dose to 10 mg if readings stay above 135/85 for a month, and to halve or stop it for dizziness, fainting or readings below 110 systolic during illness or heavy work.
2. **Vitamin D insufficiency** (E55.9). Now sufficient at 34 ng/mL. **S**
   - Continue vitamin D3 daily through the expedition.
3. **Expedition preparation** (Z71.84). Fit for the command. Vitamin C 250 mg daily is started now and stored sealed, cool and dark, because the vitamin C in stored juice and food loses strength over months; signs of scurvy (tiredness, sore gums, easy bruising, poor wound healing) to be reported to the surgeons. Mental health baseline normal. **S**
   - Vitamin C 250 mg daily from today.
   - Medical kit reviewed with the expedition's medical officer by letter: supplies for wounds, burns, frostbite, dental emergencies, infection and pain.
   - Evacuation plan: no evacuation possible for months at a time; serious illness is managed on board under his written wishes.
   - Second zoster dose today.
   - Review of medicines, blood pressure and weight on his return.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, large cuff, average of two readings) | Every visit | Completed today | 126/76 mmHg |
| Self-management | Home blood pressure monitoring | At diagnosis and two to four weeks after each treatment change, then weekly | Completed today | Average 126/78 mmHg; weekly readings on board |
| Examination | Weight, BMI and waist | Every visit | Completed today | 86.9 kg, BMI 30.1, waist 101 cm; 4.3 percent lost |
| Examination | Cardiac auscultation | Every visit | Completed today | No murmur or gallop |
| Laboratory | Basic metabolic panel, potassium and eGFR | Yearly (every six months only on a diuretic or renin-angiotensin blocker) | Completed today | Sodium 139, potassium 4.3, creatinine 0.96 mg/dL, eGFR 90: a baseline before departure |
| Laboratory | 25-hydroxyvitamin D | Three months after starting vitamin D3 | Completed today | 34 ng/mL, from 22 |
| Laboratory | Lipid panel and HbA1c or fasting glucose | Yearly | Up to date | Due on his return |
| Survey | PHQ-9 depression screen and GAD-7 | Yearly, and before isolation | Completed today | PHQ-9 2 with item 9 scored 0; GAD-7 3 |
| Medication safety | Amlodipine safety: ankle swelling, dizziness, flushing | At each visit | Completed today | No side effects; three-year supply dispensed with written dose rules |
| Self-management | Nutrition and food safety for the expedition (vitamin C and D, rations, cans, lead, botulism) | Before departure | Completed today | Vitamin C 250 mg daily from today; vitamin D3 continued; can inspection rules in writing |
| Self-management | Cold injury and hypothermia prevention | Before departure | Up to date | Training done; clothing fitted |
| Self-management | Medical kit, written plan for the ship's surgeons, and evacuation plan | Before departure | Completed today | Kit list, written plan for the surgeons, and his written wishes for serious illness on board |

## Goal progress

- Confirm or exclude hypertension with a week of home readings. Outcome by 1845-01-27: Home average 144/90 mmHg: stage 2 hypertension confirmed. **S**
- Blood pressure below 130/80 mmHg at home before departure. Outcome by 1845-04-07: Home average 127/79 mmHg at eight weeks on amlodipine 5 mg with lifestyle change. **S**
- Lose about 5 percent of body weight before sailing by his own plan of walking, hill work and smaller portions. Outcome by 1845-05-05: 90.8 to 86.9 kg (4.3 percent); waist 106 to 101 cm; he counts it as met and plans to keep walking on board. **S**
- Medical clearance for the command with a written expedition health plan, medical kit and evacuation plan. Outcome by 1845-05-05: Cleared at the pre-departure visit with no cardiac limitation; plan, kit list and supplies in hand. **S**

## Medication changes

- Started: Vitamin C (ascorbic acid) 250 mg oral tablet once daily for the whole expedition, stored sealed and away from heat and light, in addition to food sources **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, hypertension and hyperlipidemia monographs (2026), Aether Forge
- Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite: 2024 Update (2024), Wilderness Medical Society (Wilderness Environ Med 2024;35(2):183-197)
- Wilderness Medical Society Clinical Practice Guidelines for the Out-of-Hospital Evaluation and Treatment of Accidental Hypothermia: 2019 Update (2019), Wilderness Medical Society (Wilderness Environ Med 2019;30(4S):S47-S69)
- Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021 (2021), Centers for Disease Control and Prevention (MMWR Recomm Rep 2021;70(2):1-30)
- Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions (2018), U.S. Preventive Services Task Force
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Full review on his return, with lipids, HbA1c, kidney function, urine albumin and blood lead. **S**

